Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Mar 23;11(3):e0151960.
doi: 10.1371/journal.pone.0151960. eCollection 2016.

Insulin Resistance in PCOS Patients Enhances Oxidative Stress and Leukocyte Adhesion: Role of Myeloperoxidase

Victor M Victor  1   2   3   4 , Susana Rovira-Llopis  1   2 , Celia Bañuls  1   2 , Noelia Diaz-Morales  1 , Arantxa Martinez de Marañon  1 , Cesar Rios-Navarro  3 , Angeles Alvarez  3   5 , Marcelino Gomez  1 , Milagros Rocha  1   2   3 , Antonio Hernández-Mijares  1   2   6
Affiliations

Insulin Resistance in PCOS Patients Enhances Oxidative Stress and Leukocyte Adhesion: Role of Myeloperoxidase

Victor M Victor et al. PLoS One. .

Abstract

Cardiovascular diseases and oxidative stress are related to polycystic ovary syndrome (PCOS) and insulin resistance (IR). We have evaluated the relationship between myeloperoxidase (MPO) and leukocyte activation in PCOS patients according to homeostatic model assessment of IR (HOMA-IR), and have explored a possible correlation between these factors and endocrine and inflammatory parameters. This was a prospective controlled study conducted in an academic medical center. The study population consisted of 101 PCOS subjects and 105 control subjects. We divided PCOS subjects into PCOS non-IR (HOMA-IR<2.5) and PCOS IR (HOMA-IR>2.5). Metabolic and anthropometric parameters, total and mitochondrial reactive oxygen species (ROS) production, MPO levels, interactions between human umbilical vein endothelial cells and leukocytes, adhesion molecules (E-selectin, ICAM-1 and VCAM-1) and proinflammatory cytokines (IL-6 and TNF-α) were evaluated. Oxidative stress was observed in PCOS patients, in whom there was an increase in total and mitochondrial ROS production and MPO levels. Enhanced rolling flux and adhesion, and a decrease in polymorphonuclear cell rolling velocity were also detected in PCOS subjects. Increases in IL-6 and TNF-α and adhesion molecules (E-selectin, ICAM-1 and VCAM-1) were also observed, particularly in the PCOS IR group, providing evidence that inflammation and oxidative stress are related in PCOS patients. HOMA-IR was positively correlated with hsCRP (p<0.001, r = 0.304), ROS production (p<0.01, r = 0.593), leukocyte rolling flux (p<0.05, r = 0.446), E-selectin (p<0.01, r = 0.436) and IL-6 (p<0.001, r = 0.443). The results show an increase in the rate of ROS and MPO levels in PCOS patients in general, and particularly in those with IR. Inflammation in PCOS induces leukocyte-endothelium interactions and a simultaneous increase in IL-6, TNF-α, E-selectin, ICAM-1 and VCAM-1. These conditions are aggravated by the presence of IR.

PubMed Disclaimer

Conflict of interest statement

Competing Interests: The authors have declared that no competing interests exist.

Figures

Fig 1
Fig 1. Effects of PCOS on levels of ROS in PMN.
(A) Levels of DCFH-DA fluorescence measured by fluorimetry in controls and PCOS subjects; (B) Levels of DCFH fluorescence in controls and in PCOS non-IR and PCOS IR subjects; (C) Mean DCFH fluorescence assessed by static cytometry; % vs control. (D) Representative images of DCFH-DA fluorescence in PMNs assessed by fluorescence microscopy; nuclei: Hoechst 33342 signal (blue); ROS: DCFH-DA signal (green). *p<0.05 ***p<0.001 vs. Control; cp<0.001 between PCOS non-IR and PCOS IR subjects.
Fig 2
Fig 2. Leukocyte mitochondrial ROS production in PCOS non-IR and IR patients and control women.
A) Mitochondrial ROS (Mitosox Red Fluorescence) in PCOS versus control subjects. B) Mitochondrial ROS (Mitosox Red Fluorescence) in PCOS non IR and IR patients versus control subjects. Values in the bar graphs were obtained by calculating the percentage of fluorescence intensity relative to the control. *p<0.05 and **p<0.01 PCOS versus control group.
Fig 3
Fig 3. Plasma MPO concentrations in PCOS and control subjects (A) and in control, PCOS non-IR and PCOS IR subjects (B).
*p<0.05 and **p<0.01 vs. Control; ap<0.05 between PCOS non-IR and PCOS IR subjects.
Fig 4
Fig 4. Leukocyte/endothelium interactions in PCOS and control subjects.
PMN rolling velocity (μsecond-1) (A), rolling flux (PMN per minute) (C), and PMN adhesion (PMN per square millimetre) (E); and PCOS non-IR and PCOS IR subjects: PMN rolling velocity (μsecond-1) (B), rolling flux (PMN per minute) (D), and PMN adhesion (PMN per square millimetre) (F). *p<0.05 and ***p<0.001 vs. Control. ap<0.05 and bp<0.01 between PCOS non-IR and PCOS IR subjects.
Fig 5
Fig 5. Adhesion molecules in the serum of PCOS and control subjects.
(A) E-selectin, (C) ICAM-1 and (E) VCAM-1; and PCOS non-IR, PCOS IR and control subjects. (B) E-selectin, (D) ICAM-1 and (F) VCAM-1. *p<0.05, **p<0.01, ***p<0.001 with respect to the control group; ap<0.05 and bp<0.01 between PCOS non-IR and PCOS IR subjects.
Fig 6
Fig 6. Proinflammatory cytokines in the serum of PCOS and control subjects.
(A) IL-6, and (C) TNF-α; and PCOS non-IR, PCOS IR and control subjects. (B) IL-6, and (D) TNF-α. *p<0.05, **p<0.01 with respect to control group; ap<0.05 between PCOS non-IR and PCOS IR subjects.
Fig 7
Fig 7. Correlation studies of HOMA-IR and inflammation and adhesion parameters in PCOS women.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Diamanti-Kandarakis E, Kouli CR, Bergiele AT, Filandra FA, Tsianateli TC, Spina GG, et al. A survey of the polycystic ovary syndrome in the Greek island of Lesbos: hormonal and metabolic profile. J Clin Endocrinol Metab. 1999;84: 4006–4011. - PubMed
    1. Dunaif A. Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr Rev. 1997;18: 774–800. - PubMed
    1. Moran LJ, Misso ML, Wild RA, Norman RJ. Impaired glucose tolerance, type 2 diabetes and metabolic syndrome in polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod Update 2010;16: 347–363. 10.1093/humupd/dmq001 - DOI - PubMed
    1. Ehrmann DA. Polycystic ovary syndrome. N Engl J Med. 2005;352: 1223–1236. - PubMed
    1. Bajuk Studen K, Jensterle Sever M, Pfeifer M. Cardiovascular risk and subclinical cardiovascular disease in polycystic ovary syndrome. Front Horm Res. 2013;40: 64–82. 10.1159/000341838 - DOI - PubMed

Publication types

Grants and funding

This study was financed by grants PI12/1984, PI13/1025, PI13/0073, PI15/1424, CIBERehd CB06/04/0071, PROMETEOII2014/035, SAF2010/16030, UGP-14-93, UGP-14-95 and by the European Regional Development Fund (ERDF “A way to build Europe”). VMV and MR are recipients of contracts from the Ministry of Health of the Valencian Regional Government and Carlos III Health Institute (CES10/030 and CP10/0360, respectively). SR-L is the recipient of a predoctoral fellowship from Carlos III Health Institute (FI11/00637). CB is the recipient of a postdoctoral contract from Carlos III Health Institute (CD14/00043). ND-M is the recipient of a predoctoral contract from Carlos III Health Institute (FI14/00125). CR-N was supported by Conselleria de Educación, Cultura y Deporte (CPI-13-194). AA was supported by Ministerio de Ciencia e Innovación (Ramón y Cajal program RYC2005-002295 and I3 program).